Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2020-11-05 Capital/Financing Update
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the assignment of credit ratings by CARE Ratings Limited. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of credit rating reaffirmations for various bank facilities. The document is short (1531 characters) and serves as an announcement of credit rating updates rather than a financial report or detailed analysis. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company financing activities such as credit ratings.
2020-11-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended 30.09.2020, submitted to stock exchanges as per SEBI regulations. It includes details of transactions with key management personnel, promoters, and related enterprises, with amounts and balances. The document is a regulatory compliance disclosure rather than a full financial report or audit. It is relatively short (2925 characters) and serves as a formal announcement of related party transactions rather than a comprehensive report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance disclosures that do not constitute full reports or other specific filings.
2020-11-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held by the management of Hester Biosciences Limited discussing the financial results for the quarter and half year ended 30.09.2020. It includes detailed commentary on sales performance, product lines, geographic markets, and future outlook, followed by a Q&A session with investors. The presence of a moderator, management speakers, and investor questions confirms this is a full call transcript. The document length (15,000 characters) and content depth further support this classification. Therefore, the document fits the definition of a Call Transcript (CT).
2020-11-04 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated 31 October 2020, presenting financial highlights for Q2FY21 and H1FY21, including sales, net profit, EPS, division-wise sales, profitability analysis, and balance sheet analysis. It also contains detailed business overviews for various subsidiaries and future outlooks. The content includes actual financial data and analysis for the quarter and half-year periods, indicating it is a comprehensive interim financial report rather than a brief earnings release or a simple announcement. The length is 9008 characters, which supports it being a full report rather than a short announcement. There is no indication that this is an annual report or a full year report, but it clearly covers interim financial results with substantive data and commentary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-10-31 English
Financial Result Updates
Regulatory Filings
2020-10-31 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is dated 31.10.2020 and addressed to stock exchanges (BSE and NSE) with a subject line indicating the outcome of a Board Meeting. It references the approval of Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30.09.2020. The document includes detailed financial tables with quarterly and half-year figures, including revenue, expenses, profit before tax, tax expense, and earnings per share. The presence of unaudited financial results for a quarter and half year period, along with segment revenue and results, indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-10-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.